Cystic Fibrosis Foundation Invests $13M in Biotech Startup SpliSense to Advance Genetic Disorder Treatments

The Cystic Fibrosis Foundation has committed $13 million to SpliSense, a biotechnology company focused on developing precision therapies for genetic disorders, according to a press release issued on October 10, 2023. The investment aims to accelerate the development of SpliSense’s platform for targeting RNA-based mutations, a novel approach in treating conditions like cystic fibrosis, which affects over 70,000 people globally, per the Cystic Fibrosis Foundation’s 2023 report.

What is SpliSense and How Does Its Technology Work?

SpliSense, founded in 2019 and based in Tel Aviv, Israel, has developed a proprietary platform that targets specific RNA sequences to correct genetic mutations at the molecular level. The company’s approach differs from traditional gene therapy by focusing on RNA splicing, which allows for more precise and potentially safer interventions. According to a statement from SpliSense’s CEO, Dr. Maya Ben-David, the funding will support Phase II clinical trials for its lead candidate, SLS-001, which targets a common mutation in the CFTR gene responsible for cystic fibrosis.

“This technology represents a paradigm shift in how we address genetic diseases,” Ben-David said in a press briefing. “By correcting the RNA rather than the DNA, we can avoid off-target effects associated with other gene-editing methods.”

Why Is This Investment Significant?

The Cystic Fibrosis Foundation’s investment underscores growing interest in RNA-targeting therapies, a field that has seen increased funding in recent years. In 2022, the U.S. Food and Drug Administration approved two RNA-based drugs for rare genetic conditions, signaling regulatory confidence in the approach. The foundation’s $13 million contribution is among the largest single investments in SpliSense to date, following a $20 million Series B round in 2022 led by Israeli venture capital firm Piton Capital.

Dr. John L. Lefebvre, vice president of research at the Cystic Fibrosis Foundation, emphasized the potential impact of the partnership. “This investment aligns with our mission to find a cure for cystic fibrosis,” he stated. “SpliSense’s platform offers a unique opportunity to address the root cause of the disease, rather than just its symptoms.”

How Does This Compare to Other Biotech Investments?

SpliSense’s funding round places it among a growing cohort of biotech firms focused on RNA-based therapies. For instance, Moderna’s $1.2 billion investment in RNA-targeting programs for rare diseases in 2023 highlights the sector’s broader appeal. However, SpliSense’s focus on splicing correction sets it apart from companies like Alnylam Pharmaceuticals, which primarily targets RNA degradation. The Cystic Fibrosis Foundation’s backing also contrasts with previous investments in gene-editing startups like CRISPR Therapeutics, which have faced regulatory hurdles.

Analysts note that the foundation’s decision reflects a strategic shift toward therapies with clearer pathways to market. “RNA splicing correction is a relatively unexplored area, and SpliSense’s progress could position it as a leader in this niche,” said Sarah Lin, a biotech analyst at Bernstein Research.

What Are the Next Steps for SpliSense?

The $13 million investment will support SpliSense’s ongoing Phase II trials for SLS-001, which are expected to conclude by 2025. The company also plans to expand its pipeline to include therapies for other genetic disorders, such as Duchenne muscular dystrophy. Meanwhile, the Cystic Fibrosis Foundation has pledged to provide additional funding if the trials yield positive results, according to a spokesperson.

For patients and advocates, the partnership represents a critical step forward. “Every dollar invested in innovative science brings us closer to a cure,” said Emily Carter, a cystic fibrosis patient and founder of the advocacy group CF United. “We’re hopeful this technology will transform treatment options.”

What Does This Mean for the Future of Genetic Therapy?

The collaboration between the Cystic Fibrosis Foundation and SpliSense highlights the increasing role of patient advocacy groups in funding high-risk, high-reward biotech ventures. By bridging the gap between research and commercialization, such partnerships could expedite the development of breakthrough treatments. However, challenges remain, including the high cost of RNA-based therapies and the need for long-term safety data.

As the field evolves, stakeholders will be closely watching SpliSense’s progress. If successful, the company’s approach could redefine how genetic diseases are treated, offering a new model for precision medicine. For now, the investment serves as a testament to the potential of RNA-targeting technologies and the power of public-private collaboration in advancing medical science.